4D Molecular Therapeutics has signed an exclusive partnership with Otsuka to develop and commercialize its intravitreal gene therapy 4D-150 across the Asia-Pacific region, securing $85 million upfront, at least $50 million in near-term cost-sharing for global registration work, and eligibility for up to $336 million in milestones with tiered, double-digit royalties. The company also bolstered its balance sheet with approximately $93 million in equity proceeds and an additional equity commitment of up to $11 million from the Cystic Fibrosis Foundation to advance 4D-710, extending cash runway into the second half of 2028. Concurrent updates showed long-term safety and efficacy signals for 4D-150 in wet AMD and sustained activity in DME, while the global phase 3 4FRONT program accelerates toward topline readouts in 2027.
The strategic question is whether ophthalmology is poised to become the first mainstream specialty where one-time gene therapy can displace chronic biologics at scale. If 4D-150 delivers multi-year VEGF suppression with a single intravitreal administration, the business model for retina could shift from high-frequency bolus injections to front-loaded pricing with outcomes accountability, challenging revenue flows for incumbents and practice economics for retina clinics. Otsuka’s APAC rights hand 4DMT a regional operator with regulatory breadth and reimbursement muscle, while preserving U.S. and EU control where pricing innovation will be most heavily scrutinized.
This matters now because the anti-VEGF market has already stretched dosing intervals with Eylea 8 mg and Vabysmo, compressing the convenience gap gene therapy must clear. 4D-150’s phase 1/2 PRISM data show durable anatomical control, preserved vision, and a consistent dose response favoring the phase 3 dose, with no new inflammation signals through as long as 3.5 years of follow-up. In DME, 60-week SPECTRA results at the phase 3 dose demonstrated a mean BCVA gain of 9.7 letters, a CST reduction of 174 microns, and a 78% cut in supplemental injections versus projected on-label aflibercept, again without intraocular inflammation observed to date. For patients, the promise is fewer procedures and steadier disease control; for payers, the proposition is a one-time, potentially budget-disruptive expense that may still undercut lifetime biologic costs; for HCPs, it will test referral patterns, retreatment algorithms, and practice profitability tied to injection volume.
Competitive dynamics are tightening. AbbVie/REGENXBIO’s RGX-314 and other gene-based approaches are racing toward late-stage data, while incumbent biologics continue to push the limits of dosing. Differentiation will hinge on clean safety, true multi-year durability, and a payer-ready value story. That raises a near-term Medical Affairs mandate: generate robust RWE on inflammation management, retreatment criteria, and functional outcomes in both AMD and DME, and equip retina specialists to navigate gene therapy selection alongside long-acting biologics. Commercial teams should be building annuity and outcomes-based constructs that align with ophthalmology site-of-care economics and mitigate payer concerns about upfront spend, especially in markets with strict HTA gatekeeping across APAC.
The financing mix underscores a broader industry pattern: partnerships and disease-foundation capital are bridging late-stage biotech to pivotal inflection points while preserving option value on global rights. With 4FRONT-1 enrollment on track to complete in early 2026 and topline data expected in the first half of 2027, 4DMT has the cash to reach proof points in both AMD and DME and to prepare a phase 3 path in cystic fibrosis lung disease with 4D-710. The following two years will determine not only whether 4D-150 clears the clinical bar, but whether ophthalmology adopts a pay-for-durability model at scale. If it does, will payers and providers rewrite retina’s economics fast enough to make one-and-done standard of care, or will long-interval biologics keep the upper hand?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
